id	sid	eid	entity	type
eyereports-42	2	1	12	CARDINAL
eyereports-42	3	1	2011	DATE
eyereports-42	3	2	1	CARDINAL
eyereports-42	3	3	half	CARDINAL
eyereports-42	3	4	ranibizumab	PERSON
eyereports-42	3	5	vegf trap-eye	PERSON
eyereports-42	4	1	michael w. stewart mayo	PERSON
eyereports-42	4	2	jacksonville	GPE
eyereports-42	4	3	fl, usa	ORG
eyereports-42	4	4	half	CARDINAL
eyereports-42	4	5	ranibizumab	PERSON
eyereports-42	4	6	vegf trap-eye	PERSON
eyereports-42	5	1	half	CARDINAL
eyereports-42	5	2	ranibizumab	PERSON
eyereports-42	6	1	3	CARDINAL
eyereports-42	6	2	firstly	ORDINAL
eyereports-42	6	3	secondly	ORDINAL
eyereports-42	6	4	thirdly	ORDINAL
eyereports-42	6	5	half	CARDINAL
eyereports-42	6	6	ranibizumab	PERSON
eyereports-42	7	1	half	CARDINAL
eyereports-42	7	2	ranibizumab	PERSON
eyereports-42	7	3	only 8.3%	PERCENT
eyereports-42	7	4	4.2%	PERCENT
eyereports-42	8	1	half	CARDINAL
eyereports-42	8	2	8.25 days	DATE
eyereports-42	8	3	half	CARDINAL
eyereports-42	8	4	ranibizumab	PERSON
eyereports-42	8	5	4.75 days	DATE
eyereports-42	8	6	7.13 days	DATE
eyereports-42	9	1	half	CARDINAL
eyereports-42	9	2	ranibizumab	PERSON
eyereports-42	10	1	half	CARDINAL
eyereports-42	11	1	anti-vegf	ORG
eyereports-42	12	1	ranibizumab	PERSON
eyereports-42	12	2	vegf trap-eye	PERSON
eyereports-42	12	3	presen tation	PERSON
eyereports-42	12	4	miami	GPE
eyereports-42	12	5	fl	ORG
eyereports-42	12	6	february 11, 2011	DATE
eyereports-42	12	7	smith urfurth u	ORG
eyereports-42	12	8	miami	GPE
eyereports-42	12	9	fl	ORG
eyereports-42	12	10	february 11, 2011	DATE
eyereports-42	12	11	anti-vegf	PERSON
eyereports-42	13	1	anti-vegf	NORP
eyereports-42	13	2	anti-vegf	PERSON
eyereports-42	13	3	half-life.1,2	DATE
eyereports-42	13	4	half	CARDINAL
eyereports-42	13	5	first	ORDINAL
eyereports-42	14	1	several days to weeks later	DATE
eyereports-42	15	1	at least 1	CARDINAL
eyereports-42	15	2	ranibizu mab	PERSON
eyereports-42	15	3	half	CARDINAL
eyereports-42	15	4	ranibizumab	PERSON
eyereports-42	15	5	bevacizumab	PERSON
eyereports-42	16	1	ranibizumab	PERSON
eyereports-42	16	2	half	CARDINAL
eyereports-42	16	3	half	CARDINAL
eyereports-42	16	4	half	CARDINAL
eyereports-42	16	5	mw)-0.157	ORG
eyereports-42	16	6	7.4	CARDINAL
eyereports-42	16	7	half	CARDINAL
eyereports-42	18	1	log p	PERSON
eyereports-42	18	2	un	ORG
eyereports-42	18	3	two	CARDINAL
eyereports-42	20	1	1	CARDINAL
eyereports-42	21	1	ranibizumab	PERSON
eyereports-42	22	1	0.432	CARDINAL
eyereports-42	22	2	half	CARDINAL
eyereports-42	22	3	half	CARDINAL
eyereports-42	22	4	ranibizumab	PERSON
eyereports-42	24	1	half	CARDINAL
eyereports-42	24	2	ranibizumab halflife	PERSON
eyereports-42	25	1	half	CARDINAL
eyereports-42	26	1	half	CARDINAL
eyereports-42	26	2	8.25 days	DATE
eyereports-42	26	3	half	CARDINAL
eyereports-42	26	4	ranibizumab	PERSON
eyereports-42	26	5	mw-48 kd	QUANTITY
eyereports-42	28	1	1),3,4,6	CARDINAL
eyereports-42	28	2	half	CARDINAL
eyereports-42	29	1	bakri et al	PERSON
eyereports-42	29	2	ranibizumab	PERSON
eyereports-42	29	3	half	CARDINAL
eyereports-42	29	4	2.88 days	DATE
eyereports-42	29	5	4.32 days	DATE
eyereports-42	29	6	her2	PERSON
eyereports-42	29	7	ranibizumab	PERSON
eyereports-42	29	8	half	CARDINAL
eyereports-42	29	9	3.2 days	DATE
eyereports-42	29	10	5.6 days	DATE
eyereports-42	29	11	half	CARDINAL
eyereports-42	29	12	half	CARDINAL
eyereports-42	29	13	ranibizumab	PERSON
eyereports-42	29	14	2.54 days	DATE
eyereports-42	29	15	4.17 days	DATE
eyereports-42	30	1	0.43200	CARDINAL
eyereports-42	30	2	0.43564	CARDINAL
eyereports-42	30	3	4.32 days	DATE
eyereports-42	31	1	half	CARDINAL
eyereports-42	31	2	ranibizumab	PERSON
eyereports-42	31	3	2.64 days	DATE
eyereports-42	31	4	only 8.3%	PERCENT
eyereports-42	31	5	2011	DATE
eyereports-42	31	6	1	CARDINAL
eyereports-42	31	7	michael w. stewart	PERSON
eyereports-42	31	8	4500	CARDINAL
eyereports-42	31	9	jacksonville	GPE
eyereports-42	31	10	32224	DATE
eyereports-42	33	1	+1.904.953.7040	CARDINAL
eyereports-42	34	1	ranibizumab	PERSON
eyereports-42	34	2	bevacizumab	PERSON
eyereports-42	34	3	vegf trap	PERSON
eyereports-42	34	4	half	CARDINAL
eyereports-42	35	1	11 june 2011	DATE
eyereports-42	36	1	31 july 2011	DATE
eyereports-42	37	1	3.0	CARDINAL
eyereports-42	37	2	3.0	CARDINAL
eyereports-42	38	1	m.w. stewart	GPE
eyereports-42	38	2	2011	DATE
eyereports-42	38	3	italy	GPE
eyereports-42	38	4	2011	DATE
eyereports-42	38	5	1	CARDINAL
eyereports-42	38	6	e5 doi:10.4081	PERSON
eyereports-42	38	7	non -co mmerc	PRODUCT
eyereports-42	38	8	ial	ORG
eyereports-42	40	1	2011	DATE
eyereports-42	40	2	1	CARDINAL
eyereports-42	41	1	13	CARDINAL
eyereports-42	41	2	2.88 days	DATE
eyereports-42	42	1	half	CARDINAL
eyereports-42	42	2	0.45720	CARDINAL
eyereports-42	42	3	5.6 days	DATE
eyereports-42	43	1	half	CARDINAL
eyereports-42	43	2	ranibizumab	PERSON
eyereports-42	43	3	3.34 days	DATE
eyereports-42	43	4	only 4.2%	PERCENT
eyereports-42	43	5	3.2 days	DATE
eyereports-42	44	1	half	CARDINAL
eyereports-42	44	2	ranibizumab	PERSON
eyereports-42	44	3	third	ORDINAL
eyereports-42	45	1	0.49000	CARDINAL
eyereports-42	45	2	half	CARDINAL
eyereports-42	45	3	8.25 days	DATE
eyereports-42	46	1	ranibizumab	PERSON
eyereports-42	46	2	half	CARDINAL
eyereports-42	46	3	4.75 days	DATE
eyereports-42	46	4	7.13 days	DATE
eyereports-42	47	1	3	CARDINAL
eyereports-42	47	2	1	CARDINAL
eyereports-42	48	1	0.9956	CARDINAL
eyereports-42	49	1	half	CARDINAL
eyereports-42	51	1	3	CARDINAL
eyereports-42	51	2	anti-vegf	ORG
eyereports-42	51	3	3	CARDINAL
eyereports-42	51	4	13	CARDINAL
eyereports-42	51	5	half	CARDINAL
eyereports-42	54	1	half	CARDINAL
eyereports-42	54	2	at least 2	CARDINAL
eyereports-42	55	1	rabbit data5	ORG
eyereports-42	55	2	half	CARDINAL
eyereports-42	56	1	half	CARDINAL
eyereports-42	56	2	60	CARDINAL
eyereports-42	57	1	half	CARDINAL
eyereports-42	58	1	half	CARDINAL
eyereports-42	59	1	145 kd	QUANTITY
eyereports-42	59	2	half	CARDINAL
eyereports-42	59	3	4.7 days	DATE
eyereports-42	60	1	3	CARDINAL
eyereports-42	60	2	half	CARDINAL
eyereports-42	61	1	3	CARDINAL
eyereports-42	61	2	half	CARDINAL
eyereports-42	61	3	ranibizumab	PERSON
eyereports-42	62	1	2.64 days	DATE
eyereports-42	62	2	3.34 days	DATE
eyereports-42	62	3	only 8.3%	PERCENT
eyereports-42	62	4	4.2%	PERCENT
eyereports-42	64	1	half	CARDINAL
eyereports-42	64	2	ranibizumab	PERSON
eyereports-42	64	3	4.75 days	DATE
eyereports-42	64	4	7.13 days	DATE
eyereports-42	65	1	2	CARDINAL
eyereports-42	66	1	firstly	ORDINAL
eyereports-42	66	2	half	CARDINAL
eyereports-42	68	1	half	CARDINAL
eyereports-42	68	2	one	CARDINAL
eyereports-42	70	1	secondly	ORDINAL
eyereports-42	70	2	half	CARDINAL
eyereports-42	71	1	anti-vegf	NORP
eyereports-42	71	2	ranibizumab	PERSON
eyereports-42	74	1	1	CARDINAL
eyereports-42	74	2	stewart mw	PERSON
eyereports-42	74	3	2007;27	CARDINAL
eyereports-42	74	4	1196-200	CARDINAL
eyereports-42	75	1	2	CARDINAL
eyereports-42	75	2	stewart mw	PERSON
eyereports-42	75	3	rosenfeld p.	PERSON
eyereports-42	75	4	intravitreal vegf trap	ORG
eyereports-42	77	1	j ophthalmol	PERSON
eyereports-42	77	2	3	CARDINAL
eyereports-42	77	3	gaudreault j	PERSON
eyereports-42	77	4	webb w	PERSON
eyereports-42	77	5	van hoy	PERSON
eyereports-42	78	1	sci 1999;suppl 1:2142	ORG
eyereports-42	79	1	1	CARDINAL
eyereports-42	79	2	half	CARDINAL
eyereports-42	80	1	1	CARDINAL
eyereports-42	81	1	half	CARDINAL
eyereports-42	81	2	ranibizumab	PERSON
eyereports-42	82	1	half	CARDINAL
eyereports-42	82	2	bakri8	PERSON
eyereports-42	82	3	rabbit 2.88 days	DATE
eyereports-42	82	4	ranibizumab	PERSON
eyereports-42	82	5	2.89 days	DATE
eyereports-42	82	6	regeneron vte rabbit 4.79 days bakri7	PERSON
eyereports-42	83	1	nomoto12 bevacizumab rabbit 5.95 days	PRODUCT
eyereports-42	83	2	miyake13	GPE
eyereports-42	83	3	2.8 days	DATE
eyereports-42	83	4	kim14 infliximab	PERSON
eyereports-42	83	5	4.7 days	DATE
eyereports-42	83	6	gaudreault4 ranibizumab	PERSON
eyereports-42	83	7	2.63 days	DATE
eyereports-42	83	8	0.5	CARDINAL
eyereports-42	83	9	gaudreault4 ranibizumab	PERSON
eyereports-42	83	10	3.9 days	DATE
eyereports-42	83	11	mordenti6	GPE
eyereports-42	85	1	zhu10 bevacizumab human	PRODUCT
eyereports-42	85	2	6.7 days	DATE
eyereports-42	85	3	krohne9	GPE
eyereports-42	85	4	9.82 days	DATE
eyereports-42	86	1	0.5 0.49 0.48	QUANTITY
eyereports-42	86	2	0.5 1 1.5 2	QUANTITY
eyereports-42	86	3	ial	ORG
eyereports-42	87	1	14	CARDINAL
eyereports-42	88	1	2011	DATE
eyereports-42	88	2	1	CARDINAL
eyereports-42	88	3	4	CARDINAL
eyereports-42	88	4	gaudreault j	PERSON
eyereports-42	88	5	rusit j	PERSON
eyereports-42	88	6	ranibizu mab	PERSON
eyereports-42	88	7	rhufabv2	PERSON
eyereports-42	89	1	invest ophthalmol vis sci 2005;46:726-33	ORG
eyereports-42	90	1	5	CARDINAL
eyereports-42	90	2	shah jc	PERSON
eyereports-42	90	3	senapati	GPE
eyereports-42	90	4	kompella ub	PERSON
eyereports-42	90	5	half	CARDINAL
eyereports-42	91	1	2009;26:123660	CARDINAL
eyereports-42	91	2	6	CARDINAL
eyereports-42	92	1	mordenti j	PERSON
eyereports-42	93	1	1999	DATE
eyereports-42	93	2	27:536-44	DATE
eyereports-42	94	1	7	CARDINAL
eyereports-42	94	2	bakri sj	PERSON
eyereports-42	94	3	snyder mr	PERSON
eyereports-42	94	4	reid jm	PERSON
eyereports-42	95	1	intravitreal bevacizumab	ORG
eyereports-42	96	1	2007	DATE
eyereports-42	96	2	114;855-9	DATE
eyereports-42	97	1	bakri sj	PERSON
eyereports-42	97	2	snyder mr	PERSON
eyereports-42	97	3	reid jm	PERSON
eyereports-42	98	1	ranibizu mab	PERSON
eyereports-42	99	1	2179	CARDINAL
eyereports-42	100	1	9	CARDINAL
eyereports-42	100	2	krohne tu	PERSON
eyereports-42	100	3	holz fg	ORG
eyereports-42	100	4	meyer ch.	PERSON
eyereports-42	102	1	j ophthalmol 2008	PERSON
eyereports-42	102	2	146:508-12	DATE
eyereports-42	103	1	10	CARDINAL
eyereports-42	105	1	henke-fahle s	PERSON
eyereports-42	106	1	2008;115:1750-5	CARDINAL
eyereports-42	106	2	11	CARDINAL
eyereports-42	107	1	gaudreault j	PERSON
eyereports-42	107	2	beyer jc	PERSON
eyereports-42	107	3	ranibizumab	PERSON
eyereports-42	107	4	2007;27:1260	CARDINAL
eyereports-42	107	5	12	CARDINAL
eyereports-42	108	1	nomoto h	ORG
eyereports-42	108	2	kuno n	PERSON
eyereports-42	109	1	phar macokinetics	PERSON
eyereports-42	111	1	13	CARDINAL
eyereports-42	111	2	miyaki t	PERSON
eyereports-42	111	3	kakinoki m	PERSON
eyereports-42	113	1	2010;51:1606-8	DATE
eyereports-42	114	1	14	CARDINAL
eyereports-42	115	1	kim h	PERSON
eyereports-42	115	2	csaky kg	PERSON
eyereports-42	115	3	chan cc	PERSON
eyereports-42	117	1	2006	DATE
eyereports-42	117	2	82:760-6	DATE
eyereports-42	118	1	article non -co mmerc	LAW
eyereports-42	118	2	ial	ORG